Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Levomedetomidine is the levorotary enantiomer of the racemic α2-adrenergic receptor (α2-AR) agonist medetomidine.1 Unlike medetomidine or the dextrorotary enantiomer dexmedetomidine (Item No. 15581), levomedetomidine does not induce sedation or analgesia when administered alone in dogs.2 However, levomedetomidine does reduce the level of dexmedetomidine-induced sedation in dogs. Formulations containing levomedetomidine have been used as anesthetics.
WARNING This product is not for human or veterinary use.
1. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Oncotarget 8(28), 46273-46285 (2017).
2. Sedative, analgesic, and cardiovascular effects of levomedetomidine alone and in combination with dexmedetomidine in dogs. Am. J. Vet. Res. 62(4), 616-621 (2001).